All posts by: Michael Zand

About Michael Zand

Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma – Dove Medical Press

Continue reading

2017-07-10 NEWS

Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma
Dove Medical Press
Methods: Hemangioma-derived stem cells (HemSCs) were cultured with estrogen for 48–72 h; the cell viability and proliferation were evaluated with the messenger RNA (mRNA) and protein expression levels of fibroblast growth factor 2 (FGF2), vascular …

Continue reading

2017-07-10 NEWS

Forbes

Study That Claims CRISPR Causes Unwanted Mutations Is Probably Wrong
ScienceAlert
If that was the case, we would have to seriously reconsider the safety of CRISPR, especially when used on humans. But now a paper has been published online claiming it was all a mistake, and the authors of the original study were doing a “disservice to
CRISPR Gene Editing Controversy: Does It Really Cause … – ForbesForbes
Controversial CRISPR-causes-unwanted-mutations study possibly …Genetic Literacy Project

all 3 news articles »

Continue reading

2017-07-10 NEWS

Study That Claims CRISPR Causes Unwanted Mutations Is Probably Wrong
ScienceAlert
If that was the case, we would have to seriously reconsider the safety of CRISPR, especially when used on humans. But now a paper has been published online claiming it was all a mistake, and the authors of the original study were doing a “disservice to

Continue reading

2017-07-09 NEWS

Globalnews.ca

Researcher warns of risks associated with unregulated stem cell treatments
Globalnews.ca
A researcher at the University of Alberta has a warning about the dangers of unregulated stem cell treatments. While he’s a believer in the science behind stem cell therapy, Canada research chair in health law and policy Tim Caulfield told the Alberta

and more »

Continue reading

2017-07-09 NEWS

Madison.com

Billions of Dollars on the Line for Celgene With These 3 Small Biotechs
Madison.com
In 2015, Celgene forged another relationship with a small biotech specializing in treating cancer via chimeric antigen receptor Tcell (CAR-T) therapies — Juno Therapeutics. The deal involved collaboration on several of Juno’s immunotherapy candidates.

and more »

Continue reading

2017-07-08 NEWS

Monroe Evening News

Immunotherapy drug targets tumor’s genetics instead of body part
Monroe Evening News
Whatever the tumor, the more gene mutations lurking inside, the better chance your immune system has to fight back. That’s the premise behind the recent approval of a landmark drug, the first cancer therapy ever cleared based on a tumor’s genetics
Landmark Cancer Drug Spurs Immune SystemSci-Tech Today
Tumor gene testing urged to tell if drug targets your cancerKRQE News 13

all 4 news articles »